However, most of these clinical studies reporting on the inhibitor resistance mechanisms of ROS1-rearranged lung cancer were conducted with only limited samples, and only a few explored the association between treatment-emergent ROS1 point mutations and patterns of disease progression. Here, ROS1 is linked to lung cancer.